Background and Objectives: Cancer imposes a profound burden on both physical and psychological health, particularly at advanced stages, which are associated with a poor prognosis and heightened emotional distress. Psychotherapeutic interventions have gained recognition for their role in alleviating distress, enhancing the quality of life, and supporting a holistic approach to cancer care. This review examines the effectiveness of psychotherapeutic interventions in improving psychological well-being in cancer patients. Materials and Methods: Conducted as a literature review following PRISMA guidelines, this study analyzed experimental research on psychotherapeutic interventions for cancer patients published in the past decade. Literature searches were performed in PubMed, Google Scholar, the Cochrane Library, Web of Science, PsycINFO, and Consensus, supplemented by manual reference checks. The inclusion criteria focused on randomized controlled trials (RCTs). Results: The analysis included 20 RCTs spanning over three decades, evaluating interventions such as individual meaning-centered psychotherapy (IMCP), Mindfulness-Based Cognitive Therapy (MBCT), and supportive–expressive group therapy (SEGT). IMCP emerged as being particularly effective in reducing depression, anxiety, and demoralization while enhancing spiritual well-being. MBCT demonstrated significant reductions in the fear of recurrence, while SEGT effectively addressed traumatic stress and fostered social support. Although the survival benefits were inconsistently reported, psychosocial improvements, including an enhanced quality of life and emotional resilience, were consistently observed. The methodological quality varied, with nine studies meeting high-quality standards. Conclusions: Psychotherapeutic interventions, particularly IMCP and MBCT, play a critical role in oncology by alleviating distress, fostering resilience, and improving the quality of life. Integrating these approaches into routine cancer care can ensure a more holistic treatment framework that prioritizes the emotional and psychological needs of patients.

Background and Objectives: Substance use disorders (SUDs) affect millions worldwide. Despite increasing drug use, treatment options remain limited. Psychedelic-assisted therapy (PAT), integrating psychedelic substances with psychotherapy, offers a promising alternative by addressing underlying neural mechanisms. Materials and Methods: This review’s purpose is to investigate the current understanding of psychedelic therapy for treating SUDs, including tobacco, alcohol, and drug addiction. The systematic review approach focused on clinical trials and randomized controlled trials conducted from 2013 to 2023. The search was performed using PubMed, Google Scholar, and Consensus AI, following PRISMA guidelines. Studies involving psychedelics like LSD, psilocybin, ibogaine, and ayahuasca for treating various addictions were included, excluding naturalistic studies and reviews. Results: Our results highlight the key findings from 16 clinical trials investigating psychedelic therapy for SUDs. Psychedelics like psilocybin and ayahuasca showed promise in reducing alcohol and tobacco dependence, with psilocybin being particularly effective in decreasing cravings and promoting long-term abstinence. The studies revealed significant improvements in substance use reduction, especially when combined with psychotherapy. However, the variability in dosages and study design calls for more standardized approaches. These findings emphasize the potential of psychedelics in SUD treatment, though further large-scale research is needed to validate these results and develop consistent protocols. Conclusions: This research reviewed the past decade’s international experience, emphasizing the growing potential of psychedelic therapy in treating SUDs pertaining to alcohol, tobacco, and cocaine dependence. Psychedelics such as psilocybin and ketamine can reduce cravings and promote psychological well-being, especially when combined with psychotherapy. However, regulatory barriers and specialized clinical training are necessary to integrate these therapies into mainstream addiction treatment safely. Psychedelics offer a promising alternative for those unresponsive to conventional methods.

Background and Objectives: This systematic review investigates the relationship between preoperative psychological disorders and postoperative satisfaction among patients undergoing aesthetic surgery. While aesthetic procedures can enhance self-image, growing evidence indicates that underlying mental health conditions, particularly BDD, depression, and anxiety, may compromise surgical outcomes. Materials and Methods: A comprehensive literature search was performed in PubMed, the Cochrane Library, and Google Scholar between January 2010 and December 2024. Eligible observational studies assessed preoperative psychological conditions—primarily body dysmorphic disorder, depression, and anxiety—using validated instruments, such as the Body Dysmorphic Disorder Questionnaire (BDDQ), Body Dysmorphic Disorder Examination (BDDE), Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI), and structured clinical interviews, and reported postoperative patient-reported satisfaction following aesthetic surgery. Study quality was evaluated using an adapted QUIPS framework. Results: Across the 13 included studies, six reported a negative association between moderate-to-severe preoperative psychological symptoms and postoperative satisfaction, five found no significant association, and two described positive or conditional associations. Methodological heterogeneity in psychological assessment tools and satisfaction measures was a major source of divergence across studies. Despite these differences, the evidence underscores the need for standardized, validated psychological evaluation protocols in aesthetic surgery. Incorporating mental health screening into routine surgical planning can enhance ethical practice, reduce dissatisfaction, and improve long-term patient outcomes. Conclusions: These findings advocate for a multidisciplinary approach that includes psychological assessment as an essential component of patient care in aesthetic medicine.

Background/Objectives: Cystic fibrosis (CF) is a chronic genetic disease that impacts both physical and psychological health, increasing vulnerability to anxiety, depression, and reduced quality of life (QoL). Psychological interventions, particularly cognitive behavioral therapy (CBT), have demonstrated promising results in enhancing emotional resilience, treatment adherence, and QoL. This systematic review aims to evaluate the role and effectiveness of psychological interventions in improving the QoL among individuals with CF. Methods: A comprehensive literature search was conducted across the PubMed, Scopus, and PsycINFO databases for studies published between 2014 and 2024, in line with PRISMA guidelines and a registered PROSPERO protocol. Out of 162 initially identified articles, six clinical studies met the inclusion criteria. Intervention included cognitive behavioral therapy-based interventions, employing several digital or telehealth formats such as fibrosis-specific cognitive behavioral therapy (CF-CBT) and the coping and learning to manage stress (CALM) program, often delivered via telehealth. Results: Most interventions demonstrated significant reductions in depression, anxiety, and perceived stress, alongside improvements in coping self-efficacy and vitality. Cohen’s d-effect sizes ranged from moderate to large for core psychological outcomes. QoL measures, particularly vitality and emotional functioning, were significantly enhanced in most studies. Conclusions: Psychological interventions, particularly CBT and ACT, significantly improve mental health and QoL in individuals with CF, supporting their integration into routine care.

Background/Objectives: Psychotic disorders with childhood or adolescent onset pose major therapeutic challenges due to their complex etiology and variable treatment response. While pharmacogenetics and neuroimaging biomarkers have independently shown potential for guiding therapy, their combined utility remains underexplored. This study aimed to investigate whether integrating CYP2D6 pharmacogenetic profiles with structural neuroimaging findings can enhance personalized treatment and predict clinical outcomes in pediatric psychotic disorders. Methods: This prospective observational study included 63 children and adolescents (10–18 years) with DSM-5 diagnosed psychotic disorders. All patients underwent baseline MRI and standardized clinical assessments (PANSS, CGI, GAF). CYP2D6 genotyping was performed in 31 patients (49.2%), categorizing them as extensive (EMs) or intermediate metabolizers (IMs). Patients were treated with atypical antipsychotics and followed for 18 months. Outcomes included symptom severity, global functioning, and side-effect profiles. Results: EM patients demonstrated superior clinical improvement, as evidenced by a reduction in PANSS scores (from 118 to 40) and a corresponding increase in GAF scores (from 39 to 76), compared to the IM and non-tested groups. IM patients exhibited a higher prevalence of MRI abnormalities and slower response. Significant correlations emerged between CYP2D6 genotype, MRI findings, and treatment outcomes (p < 0.001). Combined biomarker profiles enhanced the prediction of therapeutic response and tolerability. Conclusions: Integrating CYP2D6 pharmacogenetic data with neuroimaging biomarkers provides valuable guidance for personalizing antipsychotic treatment in pediatric psychosis. This approach improves clinical outcomes and reduces adverse effects. Future research should further explore the integration of multimodal biomarkers in larger, longitudinal cohorts to optimize individualized psychiatric care for this vulnerable population.

Background: Emotional intelligence (EI) is an important component of adolescents’ psychological adjustment and social functioning. Creativity-based experiential approaches may support EI development through active emotional processing, reflection, and interpersonal learning; however, empirical evidence in adolescents remains limited. Methods: This quasi-experimental controlled pretest–posttest study included 47 adolescents who self-selected into an experimental group (n = 24) or control group (n = 23) according to their preference regarding participation in the training program. EI was assessed using the Schutte Self-Report Emotional Intelligence Test (SSEIT). The experimental group completed a 12-week creativity-based experiential programme, while the control group continued usual activities. Results: At post-intervention, the experimental group had significantly higher overall EI (p < 0.001, d = 1.60), AES (p < 0.001, d = 1.34), and ERO (p < 0.001, d = 1.24) scores than the control group. Although post-intervention ERS scores were also higher in the experimental group, a large ERS difference was already present at baseline and the experimental group showed no favorable descriptive change in this dimension. Utilization of emotions in problem solving did not differ significantly between groups (p = 0.090, d = 0.50). Conclusions: Participation in creativity-based experiential training was associated with higher post-intervention overall EI, AES, and ERO scores, but demonstrated limited effectiveness for ERS and UEPS. The small sample and insufficient statistical power, together with the non-randomized design and baseline ERS imbalance, preclude firm or causal conclusions. Larger randomized controlled studies using multimethod assessments and long-term follow-up are needed to establish causality, durability, and the mechanisms underlying these associations.